FAQs

How does Precision Prostate Consulting (PPC) utilize non-contrast MRI in their services?

PPC employs advanced AI-powered software called ProstatID®, developed by Bot Image. ProstatID is a cutting-edge post-processing MRI software that leverages cloud-based computing, physician workstation integration, and AI-driven image interpretation to deliver highly accurate prostate cancer diagnostics.

What is ProstatID and how does it enhance PPC's offerings?

ProstatID is North America’s first and only FDA-approved AI software specifically designed for the screening, detection, and diagnosis of prostate cancer. With a sensitivity and specificity of 93.6% (AUROC), it enables physicians to reliably detect and diagnose prostate cancer using non-contrast MRI, significantly reducing interpretation time while enhancing diagnostic confidence. This advancement leads to improved positive detection rates and a decrease in false positives.

How does PPC's specialization in prostate cancer screening, detection, diagnosis, and treatment planning benefit doctors and patients?

ProstatID aids physicians in treatment planning by providing a comprehensive view of the prostate, highlighting all suspicious lesions along with their individual risk scores. For high-risk lesions, the software presents them in two powerful 3D views within a transparent rendition of the prostate gland, offering clinicians precise cognitive targeting. By utilizing AI like ProstatID, MRI shows promise in significantly lowering the number of unnecessary biopsies performed due to false indicators. Clinical studies demonstrate that ProstatID not only reduces false positives but also increases early cancer detections. If a suspicious lesion is identified, the AI output facilitates optimal targeting for potential tumors, thus minimizing the likelihood of invasive biopsy procedures, which can come with unpleasant side effects and risks.

What sets PPC apart from other medical image interpretation services?

By integrating ProstatID into our offerings, PPC provides a superior solution that is years ahead of the competition. ProstatID is the only FDA-approved AI software for the screening, detection, and diagnosis of prostate cancer, offering detection and diagnostic capabilities that deliver 20% higher sensitivity and specificity than leading radiologists.

How does PPC ensure accuracy and quality in its interpretations?

ProstatID interprets multi-parametric and bi-parametric MRI scans using advanced machine learning techniques, including random forest algorithms and MR segmentation through deep learning. Trained on thousands of proprietary MR image sets, segmented prostate gland images, pathology results, ProstatID supports the early diagnosis of prostate cancer. The software outputs include colorized overlays of input image series, highlighting the boundaries of suspicious lesions and grading them according to a proprietary probability index value, facilitating whole gland assessments for treatment planning and interventional guidance.

Are there any potential risks or limitations associated with PPC's services?

ProstatID is the only FDA-cleared AI software designed to assist in cancer detection, screening, and diagnosis. The software is fast, accurate, and non-invasive, minimizing the need for contrast agents and reducing unnecessary biopsies due to false positives, while improving the detection of true positives.

How does PPC ensure patient privacy and confidentiality?

PPC’s integrated software and services comply with HIPAA regulations, ensuring the security and confidentiality of protected health information (PHI).

How can a patient access PPC's services?

For more information, please click here.

Are there any additional resources or support available for patients utilizing PPC's services?

A wealth of additional information and links to supporting studies can be found on the Bot Image website https://botimageai.com/.